

**ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI-29.
STORES SECTION (Hospital stores)**

Ref.No.119/H/Ivosidenib/PAC/2023-24

Dated: 04.12.2023

Sub:-Purchase of "Tablet Ivosidenib 250 mg (Tibsovo) " for the department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi-29, for the treatment of the patient Dr. Shalini Wig, on proprietary basis **Inviting comments thereon.**

The Institute is in the process to purchase "Tablet Ivosidenib 250 mg (Tibsovo)" for the department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi-29, for the treatment of the patient Dr. Shalini Wig from M/s. Ikris Pharma Network, Delhi (who is the authorized Indian Agent of M/s. Servier Pharmaceuticals, Germany on proprietary basis. The proposal submitted by M/s. Ikris Pharma Network, Delhi and PAC Certifications are attached.

The above documents are being uploaded for open information to submit objections, comments, if any, from any manufacturer regarding proprietary nature of the item within issue of 15 days from the day of issue/uploading of the notification giving reference **Ref.No.119/H/Ivosidenib/PAC/2023-24**. The comments should be received by office of Stores Officer (H), Main Hospital Store, at AIIMS New Delhi on or **before 19.12.2023 up to 12.30 p.m.**, failing which it will be presumed that any other vendor is having no comment to offer and case will be decided on merits.

Encl: Related documents enclosed.



[Signature]
भण्डार अधिकारी (H)
Store Officer (Hospital Stores)
अ.भा.आ.सं., अंसारी नगर, नई दिल्ली-29
A.I.I.M.S., Ansari Nagar, New Delhi-29

PROPRIETARY ARTICLE CERTIFICATE (PAC)

(For Drugs/Medicines)

(i) The indented goods are manufactured by :

SERVIER PHARMACEUTICALS LLC

(ii) Item Name:

TIBSOVO [IVO SIDENIB]

(iii) Item Strength:

250 mg — 180 tablets

[Dose is 500mg OD
3 months]

(iv) Reasons/Justification which makes the requirement proprietary :

Servier pharmaceuticals is the sole manufacturer of ivosidenib, approved for clinical use.
(certificates attached)

It is certified that market survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user.

Signature of TSEC

With name, Designation, Department, and Hospital/Institute/DGHS

1. Atul Batra Associate Prof of Medical Oncology, Medical Oncology, AllMS, New Delhi
22/11/23
2. Sameer Bakshi Med oncology, AllMS N-Delhi
3. Deepam Pushpam Medical oncology, AllMS, New Delhi

डॉ. दीपम पुष्पम, एम.डी., डीएम
Dr. DEEPAM PUSHPAM, M.D., DM
सहायक आचार्य / Assistant Professor
विश्वविद्यालय अर्बुदविज्ञान विभाग / Deptt. of Medical Oncology
डॉ. बी.रा.अ., सं.रो.केसर अस्पताल/Dr. B.R.A., IRCH
अ.भा.अ.स., नई दिल्ली/AIIMS, NEW DELHI-110029

आचार्य समीर बखशी / Prof. SAMEER BAKHSI
आचार्य एवं विभागाध्यक्ष / Professor & Head
चिकित्सा अर्बुदविज्ञान विभाग / Deptt. of Medical Oncology
डॉ. बी.आर.अ., आई.आर.सी.एच., अ.भा.अ.स., नई दिल्ली-29
Dr. B.R.A. I.R.C.H., A.I.I.M.S., New Delhi-29
डीएमसी पंजीकृत सं/DMC Registration No. 18936

Date: November 17, 2023

To Whomsoever it may Concern


Proprietary certificate

This is to certify and confirm IKRIS Pharma network as an authorised partner for Servier India Private Limited to provide access of Tibsovo (Ivosidenib), a proprietary product of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier.

TIBSOVO (Ivosidenib) is a prescription only medicine, belonging to the isocitrate dehydrogenase-1 (IDH1) inhibitor class of drugs. TIBSOVO is a registered trademark of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier. Tibsovo is available as a film-coated 250 mg tablet for oral administration, approved by USFDA since 2018.

The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities. In this regard on behalf of Servier India, we confirm that IKRIS Pharma network is our authorised partner for providing access in India. A copy of the prescribing information is shared with the channel partner, treating oncologist and physician for their easy reference. In case of any additional information/ queries please do not hesitate to contact us.

Sincerely,
For SERVIER INDIA Private Limited



Dr. Pierre Perez
Managing Director



Date: 15th November' 2023


To The Concerned

Subject: Confirming IKRIS Pharma network as authorised partner to provide access of Tibsovo (Ivosidenib) in India for Servier India Private Limited

Respected Sir/ Mam,

This is to confirm that TIBSOVO (Ivosidenib) is prescription only medicine, belonging to the isocitrate dehydrogenase-1 (IDH1) inhibitor class of drugs. TIBSOVO is a registered trademark of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier. Tibsovo is available as a film-coated 250 mg tablet for oral administration, approved by USFDA since 2018. The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities. In this regard on behalf of Servier India, we confirm that IKRIS Pharma network is our authorised partner for providing access in India. A copy of the prescribing information is shared with the channel partner, treating oncologist and physician for their easy reference. In case of any additional information/ queries please do not hesitate to contact us.


Best regards,



Dr. Poonam Gupta
Medical & Patient Affairs Director
Mobile +91 9920577551 – Phone (+91 22) 68 100 700
SERVIER INDIA Private Limited
1703, 17th Floor, Parinee Crescenzo, 'B' Wing, Plot Nos. C38 & 39, 'G' Block,
Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
www.servier.com



1703, 17th Floor, Parinee Crescenzo, 'B' Wing, Plot Nos. C-38 & 39, 'G' Block, Behind MCA, Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051 – India. • Tel : +91 22 6810 0700. email : servier.india@servier.com
CIN: U52310MH1985PTC037001.



Ikris

GLOBAL LIMITED

IKRIS GLOBAL LIMITED
UNIT 809,8/F, BRILL PLAZA,
84 TO KWA WAN ROAD
HONG KONG
CIN 3007218
E-Mail : info@ikrispharmanetwork.com

PROFORMA INVOICE

Number: PF/IGL/23-24/304

Date: 24-11-2023

Invoicing Address:

Shalini Wig
C/O All India Institute of Medical Sciences
Sri Aurobindo Marg, Ansari Nagar,
Ansari Nagar East, New Delhi,
Delhi 110029

Delivery Address:

Shalini Wig
C/O All India Institute of Medical Sciences
Sri Aurobindo Marg, Ansari Nagar,
Ansari Nagar East, New Delhi,
Delhi 110029

S.No	Brand Name	Active Ingredient	Dosage	Pack size	Quantity	Unit Price	Total Price
1	Tibsovo	Ivosidenib	250 mg	60 tablets	(1+1)	16,100.00	€16,100.00

Manufacturer: Servier Pharmaceuticals

Origin: Germany

Storage: 15 to 25 degree Celsius

GST 12%

€1,932.00

Grand Total

€18,032.00

Incoterms : CIF
Payment terms : Pre-Payment

BANK DETAILS:-

Bank : DBS BANK LTD
Current Account Number : 798110869
Account Holder : IKRIS GLOBAL LIMITED
Branch Address : 11TH FLOOR, THE CENTER, 99 QUEEN'S ROAD, CENTRAL,HONG KONG
Branch Code : 478
Bank Code : 016
SWIFT CODE : DHBKHKHH

**For
IKRIS GLOBAL LIMITED**

Important Instructions -

While transferring the amount, please mention the name of the remitter & country in which account is being held.
Please ensure to remit the PAYMENT ONLY on the Bank Details mentioned on the Pro Forma Invoice. IKRIS GLOBAL LIMITED has no other bank account.
Our business account name is IKRIS GLOBAL LIMITED, you must provide this exact account name to remit the payments. If not, payments will not be properly routed to our business account.

The above price is subject to Duty, Tax, Cess, Surcharge etc. if levied.

If any payments coming from third parties that are not involved in the transaction, such payments will be rejected and returned to the original remitter (a handling fee of HKD500 will also be applied)

This is a Computer Generated Invoice, does not required any signature.